Article

Biosimilars: Overview of Legislation, Policy, and Current State of Implementation

Biosimilar Webcast 1

Enduring Webcast: Biosimilars: Overview of Legislation, Policy and Current State of Implementation

This webcast was brought to you by Amgen.

The faculty for this webcast:

  • Defined therapeutic equivalence for small molecule generics
  • Described how biologics differ from small molecule drugs
  • Explained how the Biologics Price Control and Innovation Act amends the Public Health Service Act and the key requirements of the US biosimilars pathway
  • Discussed the difference between biosimilarity and interchangeability
  • Reviewed the US legislation for intellectual property and payment provisions

Length of webcast: 14 minutes

System Requirements

PC-based attendees

Required: Windows® 7, Vista, XP, 2003 Server or 2000

Macintosh®-based attendees

Required: Mac OS® X 10.4.11 (Tiger®) or newer

70575-R1-V1

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Senator Vincent Polistina (R, New Jersey)
Senator Vincent Polistina (R, New Jersey)
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo